Joseph Sliman

647 total citations
17 papers, 488 citations indexed

About

Joseph Sliman is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Joseph Sliman has authored 17 papers receiving a total of 488 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 6 papers in Epidemiology and 5 papers in Molecular Biology. Recurrent topics in Joseph Sliman's work include Clostridium difficile and Clostridium perfringens research (7 papers), Gut microbiota and health (5 papers) and Respiratory viral infections research (4 papers). Joseph Sliman is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (7 papers), Gut microbiota and health (5 papers) and Respiratory viral infections research (4 papers). Joseph Sliman collaborates with scholars based in United States, Türkiye and Canada. Joseph Sliman's co-authors include Jennifer A. Knight, Frangiscos Sifakis, David O. Schmeling, Henry H. Balfour, William Thomas, John F. Kokai‐Kun, Tracey Roberts, Heidi Whalen, Filip Dubovsky and Chenxiong Le and has published in prestigious journals such as Gastroenterology, PLoS ONE and Journal of Clinical Microbiology.

In The Last Decade

Joseph Sliman

17 papers receiving 478 citations

Peers

Countries citing papers authored by Joseph Sliman

Since Specialization

Citations

This map shows the geographic impact of Joseph Sliman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Sliman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Sliman more than expected).

Fields of papers citing papers by Joseph Sliman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Sliman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Sliman. The network helps show where Joseph Sliman may publish in the future.

Co-authorship network of co-authors of Joseph Sliman

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Sliman. A scholar is included among the top collaborators of Joseph Sliman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Sliman. Joseph Sliman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial 2019 ·The Lancet Infectious Diseases ·John F. Kokai‐Kun, Tracey Roberts, (unknown), Chenxiong Le, Heidi Whalen, Ralph W. Stevenson, Vincent J. Wacher, Joseph Sliman	59
2	1337. SYN-004 (Ribaxamase) Protects the Gut Microbiome of Patients Treated With Ceftriaxone From Disruption and Reduces the Emergence of Antimicrobial Resistance 2018 ·Open Forum Infectious Diseases ·John F. Kokai‐Kun, (unknown), (unknown), Julia Cope, Joseph Sliman	2
3	The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies 2017 ·Antimicrobial Agents and Chemotherapy ·John F. Kokai‐Kun, Tracey Roberts, (unknown), Éric Sicard, Marianne Rufiange, Richard N. Fedorak, Christian Carter, (unknown), James Longstreth, Heidi Whalen, Joseph Sliman	57
4	SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study 2017 ·Open Forum Infectious Diseases ·John F. Kokai‐Kun, Tracey Roberts, (unknown), Heidi Whalen, (unknown), Christopher da Costa, Joseph Sliman	6
5	SYN-004 (Ribaxamase) Protects the Diversity of the Gut Microbiome in Patients Receiving Intravenous Ceftriaxone Treatment 2017 ·Open Forum Infectious Diseases ·John F. Kokai‐Kun, Sheila Connelly, (unknown), (unknown), Joseph Sliman	2
6	Increased Pulmonary CO2 Excretion in Patients with Small Intestinal Bacterial Overgrowth (SIBO): Possible Implications for COPD 2017 ·Gastroenterology ·Klaus Gottlieb, (unknown), (unknown), (unknown), (unknown), Joseph Sliman, Stephen Carter	1
7	Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies 2016 ·Clinical Drug Investigation ·Tracey Roberts, John F. Kokai‐Kun, (unknown), (unknown), Heidi Whalen, J. Andrew Bristol, (unknown), James Longstreth, Kenneth C. Lasseter, Joseph Sliman	26
8	Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection 2016 ·Anaerobe ·Michael Kaleko, J. Andrew Bristol, (unknown), Todd B. Parsley, Giovanni Widmer, Saul Tzipori, Poorani Subramanian, Nur A. Hasan, (unknown), John F. Kokai‐Kun, Joseph Sliman, Annie Jones, Sheila Connelly	55
9	SYN-010 Modified-Release Lovastatin Does Not Significantly Alter Lipid Parameters at Doses that Reduce Methane and Alleviate Symptoms in Patients Suffering Irritable Bowel Syndrome with Constipation (IBS-C) 2016 ·The American Journal of Gastroenterology ·(unknown), Klaus Gottlieb, Joseph Sliman, (unknown), John F. Kokai‐Kun, (unknown), Mark Pimentel	1
10	Su1210 SYN-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, Lowered Breath Methane and Improved Stool Frequency in Patients With IBS-C: Results of a Multi-Center Randomized Double-Blind Placebo-Controlled Phase 2a Trial 2016 ·Gastroenterology ·Klaus Gottlieb, (unknown), Joseph Sliman, (unknown), (unknown), Ali Rezaie, Mark Pimentel	6
11	Accurate Identification of Excessive Methane Gas Producers Is Possible by a Single Fasting Measurement of Methane: Analysis of a Large National Database Confirms Prior Results 2016 ACG Presidential Poster Award 2016 ·The American Journal of Gastroenterology ·Klaus Gottlieb, Stephen Carter, (unknown), (unknown), Chenxiong Le, (unknown), Joseph Sliman	1
12	Tu2054 SYN-004, a Clinical Stage Oral Beta-Lactamase Therapy, Protects the Intestinal Microflora from Antibiotic-Mediated Damage in Humanized Pigs 2015 ·Gastroenterology ·Sheila Connelly, Giovanni Widmer, (unknown), Kevin Huynh, J. Andrew Bristol, (unknown), Joseph Sliman, Saul Tzipori, Michael Kaleko	7
13	Safety and immunogenicity of a live attenuated intranasal vaccine against respiratory syncytial virus in healthy RSV seronegative children 5 to 24 months of age. 2013 ·PLoS ONE ·Elissa Malkin, Ram Yogev, Nazha Abughali, Joseph Sliman, (unknown), (unknown), C. Yang, (unknown), Mark T. Esser, Roderick S. Tang, Filip Dubovsky	6
14	Age-Specific Prevalence of Epstein–Barr Virus Infection Among Individuals Aged 6–19 Years in the United States and Factors Affecting Its Acquisition 2013 ·The Journal of Infectious Diseases ·Henry H. Balfour, Frangiscos Sifakis, Joseph Sliman, Jennifer A. Knight, David O. Schmeling, William Thomas	180
15	Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age 2013 ·PLoS ONE ·Elissa Malkin, Ram Yogev, Nazha Abughali, Joseph Sliman, (unknown), (unknown), (unknown), Mark Eickhoff, Mark T. Esser, Roderick S. Tang, Filip Dubovsky	58
16	Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow‐fill‐seal device in adults: a randomized, active‐controlled study* 2012 ·Influenza and Other Respiratory Viruses ·Eric Sheldon, Robert Jeanfreau, Joseph Sliman, (unknown), Matthew D. Rousculp, Filip Dubovsky, Raburn M. Mallory	13
17	Outbreak of Acute Respiratory Disease Caused by Mycoplasma pneumoniae on Board a Deployed U.S. Navy Ship 2009 ·Journal of Clinical Microbiology ·Joseph Sliman, David Metzgar, (unknown), (unknown), Dennis J. Faix, Stephen E. Lizewski	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact